ArticleNeuro-oncology2011
Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.
Sylwia Ammoun et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
31 papers cite it
this paperpooled itcites it